Glenmark launches Prasugrel for the first time in India
04/29/2010

Glenmark Pharmaceuticals Limited has launched for the first time in India - ‘Prasugrel’ a revolutionary new anti-platelet drug for the management of Acute Coronary Syndrome with PCI (Percutaneous Coronary Intervention). PCI is better known as the angioplasty procedure which normally includes the placement of a stent to keep the artery open.

Online PR News – 29-April-2010 – – Glenmark launches Prasugrel for the first time in India
· A revolutionary new antiplatelet drug for the management of Acute Coronary Syndrome with PCI
· Estimated market size at Rs. 300 crores

Mumbai April 29, 2010 : Glenmark Pharmaceuticals Limited has launched for the first time in India - ‘Prasugrel’ a revolutionary new anti-platelet drug for the management of Acute Coronary Syndrome with PCI (Percutaneous Coronary Intervention). PCI is better known as the angioplasty procedure which normally includes the placement of a stent to keep the artery open.

Prasugrel will be marketed in India by Glenmark as ‘Aplet’. It is an oral anti-platelet medicine specifically for patients who have undergone an angioplasty procedure to open up a blocked heart artery after experiencing a heart attack or heart-related chest pain at rest (unstable angina) - Both these medical conditions are known as Acute Coronary Syndrome.

Prasugrel (Aplet) offers an effective alternative to current oral anti-platelet drugs which have several limitations including slow onset of action, interpatient variability and possibility of poor or no response in some patient’s especially those who are diabetic. The estimated market size for this product is Rs. 300 crores.

Commenting on this development, Mr. Rajeev Sibal, Vice President - India Formulations, Glenmark Pharmaceuticals Limited mentions “With the introduction of Aplet, Glenmark has provided a superior anti-platelet medicine for the management of patients who have Acute Coronary Syndrome with PCI. He further added “Glenmark will continue its efforts of introducing first to market products across therapeutic categories in the country”

Clinical studies have shown that treatment with Prasugrel helps to reduce the risk of a future heart-related event, such as a heart attack or stent clot, in patients who had an ACS event that was treated with angioplasty.


About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.], Metabolic Disorders [diabetes, obesity, etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres.